

*The Anti-Mullerian hormone as a predictor of intra-cytoplasmic sperm injection outcome in patients with polycystic ovary syndrome*

*Thesis submitted for partial fulfillment of the M.D. degree  
In Obstetrics & Gynecology*

*BY*

**Walid El-Sayed Elnagar**

Assistant lecturer of Obstetrics & Gynecology  
Faculty of Medicine, Al-Azhar University

**Under Supervision of**

**Dr. Abd Elmoneim Mohammad Farag**

Professor of Obstetrics & Gynecology  
Faculty of Medicine, Al-Azhar University

**Dr. Khaled Zakaria Elsheikha**

Professor of Obstetrics & Gynecology  
Faculty of Medicine, Al-Azhar University

**Dr. Aida Mohammad Ibrahim**

Professor of Clinical Pathology  
Faculty of Medicine, Al-Azhar University

**Dr. Mohammad Saleh Nawarah**

Assistant Professor of Obstetrics & Gynecology  
Faculty of Medicine, Al-Azhar University

**Dr. Adel El-Sayed Ibrahim**

Assistant Professor of Obstetrics & Gynecology  
International Islamic Center for Population Studies and Research  
(IICPSR), Al-Azhar University

**Faculty of Medicine- Al-Azhar University**

**2014**

**الهرمون المضاد لعامل موليريان كمؤشر لنتائج الحقن المجهرى  
فى المرضى المصابات بملازمة تكيس المبيض  
رسالة توطئة للحصول على درجة الدكتوراه فى التوليد وأمراض النساء**

**مقدمة من**

**الطبيب/ وليد السيد النجار**

بكالوريوس الطب والجراحة - ماجستير التوليد وأمراض النساء  
مدرس مساعد بقسم التوليد وأمراض النساء - كلية الطب - جامعة الأزهر

**تحت إشرافه**

**د. عبدالمنعم محمد فرج**

أستاذ التوليد وأمراض النساء  
كلية الطب - جامعة الأزهر

**د. خالد زكريا الشیخة**

أستاذ التوليد وأمراض النساء  
كلية الطب - جامعة الأزهر

**د. عایدة محمد إبراهيم**

أستاذ الباثولوجى الإكلینیكى  
كلية الطب - جامعة الأزهر

**د. محمد صالح نواره**

أستاذ مساعد التوليد وأمراض النساء  
كلية الطب - جامعة الأزهر

**د. عادل السيد إبراهيم**

أستاذ مساعد التوليد وأمراض النساء  
المركز الإسلامى الدولى للأبحاث و الدراسات السكانية  
جامعة الأزهر

**كلية الطب - جامعة الأزهر**

**2014**



قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا  
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة (آية ٣٢)

## ***Acknowledgements***

*First and foremost I feel always indebted to ALLAH, the Most Beneficent and Merciful.*

*I would first like to express my unlimited gratitude and thankfulness to **Dr. Abd Elmoneim Mohammad Farag** Professor of Obstetrics and Gynecology, Faculty of Medicine, Al-Azhar University, for his acceptance to supervise my work and for his continuous support, his valuable advises and encouragement without his encourage and help I would not have been able to finish this work.*

*Many thanks to **Dr. Khaled Zakaria Elsheikha** Professor of Obstetrics and Gynecology, Faculty of Medicine, Al-Azhar University for his keen supervision and his continuous wise guidance and fruitful criticism which have been of great help in presenting this work in forceful form .*

*My deepest gratitude and appreciation are to **Dr. Aida Mohammad Ibrahim** Professor of Clinical Pathology, Faculty of Medicine, Al-Azhar University, who showed me the way and the first steps for going on into this work, who helped me much and his continuous guidance.*

*I am greatly honored to express my gratitude to **Dr. Mohammad Saleh Nawarah** assistant Professor of Obstetric and Gynecology, Faculty of Medicine, Al-Azhar University, for his valuable direction, encouragement and scientific supervision.*

*I am deeply grateful to **Dr. Adel El-Sayed Ibrahim**, Assistant Professor of Obstetrics and Gynecology, International Islamic Center for Population Studies and Research (IICPSR), Al-Azhar University, for his generous help and valuable comments during the preparation of this work.*

*Lastly I feel thankful to my parents, my wife and every person who helped me and illuminated the way for performing this work.*

---

# List of Contents

|                                       | <i>Page</i> |
|---------------------------------------|-------------|
| <b>Introduction .....</b>             | <b>1</b>    |
| <b>Aim of the Work .....</b>          | <b>4</b>    |
| <b>Review of Literature:-</b>         |             |
| <b>Polycystic ovary syndrome.....</b> | <b>5</b>    |
| ➤ Historical consideration.....       | 5           |
| ➤ Prevalence.....                     | 6           |
| ➤ Diagnosis.....                      | 8           |
| ➤ Pathophysiology.....                | 10          |
| ➤ Clinical features of PCOS.....      | 21          |
| ➤ Laboratory evaluation.....          | 29          |
| ➤ Management.....                     | 32          |
| <b>OVARIAN RESERVE.....</b>           | <b>52</b>   |
| ➤ Introduction.....                   | 52          |
| ➤ Assessment of ovarian reserve.....  | 54          |
| ➤ Static tests.....                   | 54          |
| ➤ Dynamic tests.....                  | 65          |
| ➤ Antimüllerian hormone.....          | 67          |

|                                                       |                |
|-------------------------------------------------------|----------------|
| <b>ICSI .....</b>                                     | <b>78</b>      |
| ➤ <b>Introduction.....</b>                            | <b>78</b>      |
| ➤ <b>Indication.....</b>                              | <b>78</b>      |
| ➤ <b>Oocyte handling prior to microinjection.....</b> | <b>79</b>      |
| ➤ <b>Sperm handling prior to microinjection.....</b>  | <b>97</b>      |
| ➤ <b>Outcome parameters of ICSI.....</b>              | <b>98</b>      |
| ➤ <b>Embryo transfer.....</b>                         | <b>100</b>     |
| ➤ <b>Management of the luteal Phase.....</b>          | <b>103</b>     |
| <br><b>Patients and Methods .....</b>                 | <br><b>107</b> |
| <br><b>Results .....</b>                              | <br><b>117</b> |
| <br><b>Discussion .....</b>                           | <br><b>133</b> |
| <br><b>Summary .....</b>                              | <br><b>145</b> |
| <br><b>Conclusion and Recommendations .....</b>       | <br><b>151</b> |
| <br><b>References .....</b>                           | <br><b>152</b> |
| <br><b>Arabic Summary .....</b>                       | <br><b>___</b> |

## List of figure

| figure no.         | Details                                                                                                           | Page no. |
|--------------------|-------------------------------------------------------------------------------------------------------------------|----------|
| <b>REVIEW</b>      |                                                                                                                   |          |
| 1                  | Aetiology and clinical features of polycystic ovary syndrome                                                      | 10       |
| 2                  | ovarian theca cells respond to luteinizing hormone (LH) by increasing androgenic precursor output                 | 11       |
| 3                  | The two hit hypothesis of polycystic ovary syndrome                                                               | 13       |
| 4                  | insulin resistance leads to hepatic overproduction of apoB and VLDL                                               | 19       |
| 5                  | Shown more than 12 ovarian cysts of 2 mm to 5 mm in diameter spanning the perimeter of the left and right ovaries | 27       |
| 6                  | AMH produced by granulosa cells from primordial follicle                                                          | 69       |
| 7                  | correlation between serum AMH and age                                                                             | 70       |
| 8                  | Human prezygote with two pronuclei on day 1                                                                       | 98       |
| <b>METHODOLOGY</b> |                                                                                                                   |          |
| 9                  | Oocyte grading                                                                                                    | 112      |
| 10                 | Oocyte 16-18h after insemination                                                                                  | 114      |
| 11                 | Grading of embryos 48h after insemination                                                                         | 115      |
| <b>RESULTS</b>     |                                                                                                                   |          |
| 12                 | Pie chart for the distribution of studied cohort by response.                                                     | 120      |
| 13                 | Hormonal profiles and antral follicle count (AFC) of the studied poor and normal responders                       | 122      |

|           |                                                                                                                                         |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------|-----|
| <b>14</b> | Poor response and Normal response in low, moderate and high level of serum AMH groups                                                   | 123 |
| <b>15</b> | Pie chart for the distribution of normal responders by pregnancy outcome                                                                | 124 |
| <b>16</b> | Hormonal profiles and antral follicle count (AFC) of the studied positive and negative pregnancy in the studied normal responders       | 126 |
| <b>17</b> | Pregnancy rate in low, moderate and high level of serum AMH groups.                                                                     | 127 |
| <b>18</b> | Distribution of normal responders by pregnancy outcome (Oocyte number, fertilized embryo, grade A embryo and number of embryo transfer) | 129 |
| <b>19</b> | Correlations between serum AMH (ng /ml) and the age in low, moderate and high level of serum AMH groups.                                | 130 |

## List of Tables

| Table no.          | Details                                                                                                     | Page no. |
|--------------------|-------------------------------------------------------------------------------------------------------------|----------|
| <b>REVIEW</b>      |                                                                                                             |          |
| 1                  | Commonly used definition of polycystic ovary syndrome                                                       | 8        |
| 2                  | Interpretations of 2-hour glucose test                                                                      | 31       |
| 3                  | Markers of ovarian reserve                                                                                  | 54       |
| 4                  | Interpretation day 3 level of FSH according to <i>Advanced Fertility Center of Chicago</i> reports          | 56       |
| <b>METHODOLOGY</b> |                                                                                                             |          |
| 5                  | Oocyte grading                                                                                              | 110      |
| <b>RESULTS</b>     |                                                                                                             |          |
| 6                  | Causes of cycle cancellation in the study cohort                                                            | 120      |
| 7                  | Distribution of the studied poor and normal responders by demographical and clinical parameters.            | 121      |
| 8                  | Poor response and Normal response in low, moderate and high level of serum AMH groups.                      | 123      |
| 9                  | Distribution of normal responders by pregnancy outcome                                                      | 124      |
| 10                 | Age and BMI and duration of infertility distribution of the studied normal responders by pregnancy outcome. | 125      |

|           |                                                                                                                                                                      |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| <b>11</b> | Hormonal profiles and antral follicle count (AFC) of the studied positive and negative pregnancy in the studied normal responders                                    | 125 |
| <b>12</b> | Pregnancy rate in low, moderate and high level of serum AMH groups.                                                                                                  | 126 |
| <b>13</b> | Gonadotropine (Gn) days, dose, follicle number, and E2 hCG in the studied normal responders by pregnancy outcome.                                                    | 127 |
| <b>14</b> | Distribution of normal responders by pregnancy outcome (Oocyte number, fertilized embryo, grade A embryo and number of embryo transfer)                              | 128 |
| <b>15</b> | Correlations between serum AMH (ng /ml) and (age, BMI).                                                                                                              | 129 |
| <b>16</b> | Correlations between serum AMH (ng /ml) and the age in low, moderate and high level of serum AMH groups.                                                             | 130 |
| <b>17</b> | Correlations between serum AMH (ng /ml) and hormonal profile and AFC.                                                                                                | 131 |
| <b>18</b> | Correlations between serum AMH (ng /ml) and AFC in low, moderate and high level of serum AMH groups.                                                                 | 131 |
| <b>19</b> | Correlations between serum AMH (ng /ml) and (E2 at hCG, No. Ampoule, Oocyte number, No. of Total of embryos, No. of grade A embryos and No. of transferred embryos). | 132 |

**List of abbreviations**

|                 |                                                  |
|-----------------|--------------------------------------------------|
| 3D              | Three Dimension                                  |
| 17 $\alpha$ -HP | 17 (Alpha) Hydroxyprogesterone                   |
| ACTH            | Adrenocorticotrophic Hormone                     |
| AES             | Androgen Excess Society                          |
| AFC             | Antral Follicle Count                            |
| Als             | Aromatase Inhibitors                             |
| AMH             | Anti-Müllerian Hormone                           |
| Apo B           | Apolipoprotein B                                 |
| AR              | Androgen Receptor                                |
| Arts            | Assisted Reproductive Techniques                 |
| BMI             | Body Mass Index                                  |
| Bmps            | Bone Morphogenetic Proteins                      |
| CAH             | Congenital Adrenal Hyperplasia                   |
| CBAVD           | Congenital Bilateral Absence Of The Vas Deferens |
| CC              | Clomiphene Citrate                               |
| CCCT            | Clomiphene Citrate Challenge Test                |
| COH             | Controlled Ovarian Hyperstimulation              |
| CVD             | Cardiovascular Disease                           |
| DET             | Double Embryo Transfer                           |
| DHEA-S          | Dehydroepiandrosterone-Sulfate                   |

---

## *List of abbreviations*

---

|            |                                                                                                       |
|------------|-------------------------------------------------------------------------------------------------------|
| DM2        | Diabetes Mellitus Type 2                                                                              |
| E2         | Estradiol                                                                                             |
| EFFORT     | Exogenous FSH Ovarian Reserve Test                                                                    |
| ER         | Estrogen Receptors                                                                                    |
| ESHRE/ASRM | European Society For Human Reproduction And Embryology And American Society For Reproductive Medicine |
| ET         | Embryo Transfer                                                                                       |
| Ffas       | Free Fatty Acides                                                                                     |
| FSH        | Follicle Stimulating Hormone                                                                          |
| GAST       | GnRh Agonist Stimulation Test                                                                         |
| Gcs        | Granulosa Cells                                                                                       |
| GDM        | Gestational Diabetes                                                                                  |
| GH         | Growth Hormone                                                                                        |
| Gnrh       | Gonadotrophin Releasing Hormone                                                                       |
| Gnrha      | Gonadotrophin Releasing Hormone Agonist                                                               |
| GWAS       | Comprehensive Genome-Wide Association Studies                                                         |
| HCG        | Human Chorionic Gonadotropin                                                                          |
| HDL-C      | High-Density Lipoprotein Cholesterol                                                                  |
| HMG        | Human Menopausal Gonadotropin                                                                         |
| HPA        | Hypothalamic–Pituitary–Adrenal                                                                        |
| HPO        | Hypothalamic–Pituitary–Ovarian                                                                        |

---

## *List of abbreviations*

---

|         |                                                                    |
|---------|--------------------------------------------------------------------|
| ICSI    | Intracytoplasmic Sperm Injection                                   |
| IGFBP-1 | Insulin Growth Factor Binding Protein-1                            |
| IGF-I   | Insulin-Like Growth Factor-I                                       |
| IGT     | Impaired Glucose Tolerance                                         |
| IICPRS  | International Islamic Center For Population Researches And Studies |
| IM      | Intramuscular                                                      |
| IRs     | Insulin Receptors                                                  |
| IUI     | Intra Uterine Insemination                                         |
| IVF     | In Vitro Fertilization                                             |
| LDL-C   | Low-Density Lipoprotein Cholesterol                                |
| LGA     | Large For Gestational Age                                          |
| LH      | Luteinizing Hormone                                                |
| LOD     | Laparoscopic Ovarian Drilling                                      |
| LOS     | Laparoscopic Ovarian Surgery                                       |
| LPL     | Lipoprotein Lipase                                                 |
| MRI     | Magnetic Resonance Imaging                                         |
| NCAH    | Non-Classical Adrenal Hyperplasia                                  |
| NIEHS   | National Institute Of Environmental Health Sciences                |
| NIH     | National Institutes Of Health                                      |
| OA      | Ovarian Area                                                       |
| Ocps    | Oral Contraceptive Pills                                           |

---

---

*List of abbreviations*

---

|       |                                   |
|-------|-----------------------------------|
| OHSS  | Ovarian Hyperstimulation Syndrome |
| OPU   | Ovum Pickup                       |
| OR    | Ovarian Reserve                   |
| PCOS  | Polycystic Ovary Syndrome         |
| PGD   | Preimplantation Genetic Diagnosis |
| PI    | Pulsatility Index                 |
| PN    | Pronuclei                         |
| PSV   | Peak Systolic Velocity            |
| PVP   | Polyvinyl Pyrrolidone             |
| PZD   | Partial Zona Dissection           |
| RCT   | Randomized Controlled Trials      |
| rFSH  | Recombinant FSH                   |
| RI    | Resistance Index                  |
| SET   | Single Embryo Transfer            |
| SGA   | Small for Gestational Age         |
| SHBG  | Sex Hormone Binding Globulin      |
| SUZI  | Subzonal Insemination             |
| TGFb  | Transforming Growth Factor-b      |
| TSH   | Thyroid Stimulating Hormone       |
| TVOD  | Transvaginal Ovarian Drilling     |
| TV-US | Transvaginal Ultrasound           |

---

## *List of abbreviations*

---

|      |                                    |
|------|------------------------------------|
| VEGF | Vascular Endothelial Growth Factor |
| VLDL | Very Low-Density Lipoprotein       |
| WHO  | World Health Organization          |

---